Unlike buprenorphine, which any appropriately registered provider can now prescribe, methadone for opioid use disorder remains restricted to federally certified Opioid Treatment Programs — worth understanding why, including the ongoing debate about whether this should change.
The historical reason: Methadone regulations date back decades, rooted partly in methadone’s status as a full opioid agonist with real overdose risk if mismanaged, and partly in a regulatory framework built when far less was known about safely managing opioid use disorder with medication.
The case for keeping current restrictions: Structured, supervised dosing — especially during induction, the highest-risk period — provides a safety net that decentralized prescribing wouldn’t automatically include, proponents argue.
The case against current restrictions: Critics, including some addiction medicine specialists, argue the restriction reflects outdated stigma more than current clinical evidence, and that it creates unnecessary access barriers — particularly in rural areas far from any OTP — compared to how other high-risk medications are regulated.
Where this stands now: The 2024 SAMHSA final rule expanded flexibility within the existing OTP-based system (take-home doses, telehealth, higher initial dosing) rather than removing the OTP requirement itself. Whether methadone prescribing will eventually expand beyond OTPs, similar to what happened with buprenorphine after the X-waiver was eliminated, remains an active policy discussion, not a settled question.
Medically reviewed by [pending]. Sources: 42 CFR Part 8, SAMHSA 2024 Final Rule, policy literature on OTP regulatory reform debates.